J
James R. Yankaskas
Researcher at University of North Carolina at Chapel Hill
Publications - 73
Citations - 7959
James R. Yankaskas is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Cystic fibrosis & Cystic fibrosis transmembrane conductance regulator. The author has an hindex of 41, co-authored 73 publications receiving 7729 citations. Previous affiliations of James R. Yankaskas include National Institutes of Health & University of Michigan.
Papers
More filters
Journal ArticleDOI
Submucosal glands are the predominant site of CFTR expression in the human bronchus.
John F. Engelhardt,James R. Yankaskas,Stephen A. Ernst,Yiping Yang,Christopher R. Marino,Richard C. Boucher,Jonathan A. Cohn,James M. Wilson +7 more
TL;DR: The data suggest mechanisms whereby defects in CFTR expression could lead to abnormal production of mucus in human lung, particularly in non–CF individuals.
Journal ArticleDOI
An Official American Thoracic Society Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses
Paul N. Lanken,Peter B. Terry,Horace M. DeLisser,Bonnie Fahy,John Hansen-Flaschen,John E. Heffner,Mitchell M. Levy,Richard A. Mularski,Molly L. Osborne,Thomas J. Prendergast,Graeme Rocker,William J. Sibbald,Benjamin S. Wilfond,James R. Yankaskas +13 more
TL;DR: This paper discusses the decision-making process for withdrawing mechanical Ventilation in palliative care and some of the management techniques used in this process.
Journal ArticleDOI
Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections
Gerald B. Pier,Martha Grout,Tanweer Zaidi,John C. Olsen,Larry G. Johnson,James R. Yankaskas,Joanna B. Goldberg +6 more
TL;DR: Pseudomonas aeruginosa lipopolysaccharide (LPS)-core oligosaccharide was identified as the bacterial ligand for epithelial cell ingestion; exogenous oligosACcharide inhibited bacterial ingestion in a neonatal mouse model, resulting in increased amounts of bacteria in the lungs.
Journal ArticleDOI
Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans
Barbara R. Grubb,Raymond J. Pickles,Hong Ye,James R. Yankaskas,Ralph N. Vick,John F. Engelhardt,James M. Wilson,Larry G. Johnson,Richard C. Boucher +8 more
TL;DR: It is found that even repeated high doses can only partially correct the CF defect in Cl− transport in vivo and do not correct the Na+ transport defect at all, and indicates that more efficient adenoviral gene-transfer vectors and/or refinement of dosing strategies are needed for therapy of CF lung disease.
Journal ArticleDOI
Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice.
Lane L. Clarke,Barbara R. Grubb,James R. Yankaskas,Calvin U Cotton,Andrew McKenzie,Richard C. Boucher +5 more
TL;DR: It is concluded that there is an intracellular Ca(2+)-regulated Cl- conductance that is molecularly distinct from CFTR and the level of expression of this alternative Cl- Conductance in the epithelium is an important determinant of the severity of organ-level disease in CF.